Your Mouth on a Chip
NIH ' s National Institute of Dental and Craniofacial ResearchCell-loaded microchips offer a new lens into human biologyMicrochips that mimic parts of the human body may sound futuristic, but these devices —called organs-on-chips—are already being used to study human biology. Made from plastic, with grooves that are lined with cells and channels that transport air and fluids, these chips can simulate aspects of organ structure and function. Chips have been designed to mimic many different parts of the body, including beating heart tissue, air-filtering lung cells, and electrically active brain cells. The technolo...
Source: Dental Technology Blog - March 10, 2022 Category: Dentistry Source Type: news
Wistar Institute receives largest individual philanthropic gift in its 50-year history
The Wistar Institute has received the largest individual philanthropic gift in its 50-year history, and it plans to use the donation to support its efforts to continue discovering promising cancer therapies.
The $10 million gift was made by Ronald Caplan, founder and president of PMC Property Group Inc., and his wife Ellen.
The donation will support Wistar’s National Cancer Institute-designated Cancer Center, which will be renamed the Ellen and Ronald Caplan Cancer Center of The Wistar Institute.… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 9, 2022 Category: Pharmaceuticals Authors: John George Source Type: news
Wistar Institute receives largest individual philanthropic gift ever
The Wistar Institute has received the largest individual philanthropic gift ever, and plans to use the donation to support its efforts to continue discovering promising cancer therapies.
The $10 million gift was made by Ronald Caplan, founder and president of PMC Property Group Inc., and his wife Ellen.
The donation will support Wistar’s National Cancer Institute-designated Cancer Center, which will be renamed the Ellen and Ronald Caplan Cancer Center of The Wistar Institute. T he money, Wistar… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - March 9, 2022 Category: Health Management Authors: John George Source Type: news
COVID-19 vaccination programme, RCGP (updated 8th March 2022)
The latest updates on the COVID-19 vaccine. Update in this version (published 8th March 2022) – updated ' Information for healthcare professionals on blood clotting following COVID-19 vaccination ' and ' Clinician FAQs and guidance on COVID-19 vaccine for patients receiving Systemic Anti-Cancer Therapy (SACT) ' . Update in version published 13th January 2022 - added ' Vaccines in Pregnancy Screencast ' . (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 9, 2022 Category: Consumer Health News Source Type: news
Women Who Lead: Getting the right cancer treatment to the right person at the right time
Managing the supply chain for personalized cancer therapies is no easy task — and the stakes couldn't be higher. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 4, 2022 Category: Biotechnology Authors: Elizabeth Moss Source Type: news
Atrial Fib, Elevated Lipids Raise Stroke Risk in Cancer Patients Atrial Fib, Elevated Lipids Raise Stroke Risk in Cancer Patients
New-onset or pre-existing AF predicted acute ischemic stroke or TIA in patients with cancer -- as did renal disease, dyslipidemia, and active cancer therapy -- in a case-control study.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 24, 2022 Category: Cancer & Oncology Tags: Cardiology News Source Type: news
Women Face Higher Risk for Severe AEs From Cancer Therapy
Large differences in risks for severe adverse events according to sex seen for cancer patients receiving immunotherapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 23, 2022 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Journal, Source Type: news
Women Face Higher Risk for Severe AEs From Cancer Therapy
WEDNESDAY, Feb. 23, 2022 -- Women are at higher risk than men for severe cancer treatment-related adverse events (AEs), particularly for immunotherapy, according to a study published online Feb. 4 in the Journal of Clinical Oncology.
Joseph M.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 23, 2022 Category: Pharmaceuticals Source Type: news
Breast Cancer Therapy-Related Cardiac Dysfunction Likely Diagnosed More Accurately With Combined Testing Breast Cancer Therapy-Related Cardiac Dysfunction Likely Diagnosed More Accurately With Combined Testing
In women with HER2-positive breast cancer, combined sequential use of echocardiographic 3-D LVEF with 2-D GLS and GCS provided a more timely and accurate diagnosis of cancer therapy-related cardiac dysfunction than when these measures were used individually.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - February 22, 2022 Category: Radiology Tags: Hematology-Oncology News Source Type: news
Women at Higher Risk of Serious Adverse Events From Cancer Therapy Women at Higher Risk of Serious Adverse Events From Cancer Therapy
Women are more likely to have serious adverse events when treated with chemotherapy and targeted agents, and especially so with immunotherapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 17, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
New ERLEADA ® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
SAN FRANCISCO, Feb. 14, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA® (apalutamide) results in high rates of rapid and deep prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC). In a separate post-hoc analysis of the registrational Phase 3 SPARTAN and TITAN studies, rapid and deep PSA responses with ERLEADA® were associated with improvement in patient-reported outcomes (PROs) related to quality of life, physical wellbeing, pain, and fatigue intensity. The...
Source: Johnson and Johnson - February 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Echo algorithm can diagnose cardiac dysfunction from cancer therapy
A clinical algorithm that combines echocardiography with measurement of tissu...Read more on AuntMinnie.comRelated Reading:
Echocardiography can determine patient risk in COVID-19 cases
Prenatal detection of heart defects low in Hispanic women, poor areas
AI-guided echo helps novice nurses perform ultrasound
Echo screening reduces rheumatic heart disease in kids in Nepal
Echo helps identify flossing-induced heart disease (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 11, 2022 Category: Radiology Source Type: news
TMC Innovation selects 20 participants for cancer therapeutics accelerator
The cancer therapies accelerator was created with grant funding from the Cancer Prevention Research Institute of Texas, or CPRIT. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - February 9, 2022 Category: American Health Authors: Chris Mathews Source Type: news
UCLA scientists identify biomarker signature that predicts side effects from some cancer treatments
UCLA Jonsson Comprehensive Cancer Center researchers have identified a biomarker signature that predicts which patients are likely to be affected by serious side effects that can occur during a type of cancer treatment.The study, led by Dr. Joanne Weidhaas, a UCLA professor of radiation oncology and the director of the division of molecular and cellular oncology at UCLA Health, was published in the Journal for ImmunoTherapy of Cancer.The study focused onanti-PD1/PDL1 therapy, which has emerged as a promising approach for treating several types of cancer but which causes serious side effects in up to 30% of patients. T...
Source: UCLA Newsroom: Health Sciences - February 4, 2022 Category: Universities & Medical Training Source Type: news
Alpha Tau Announces New Research Collaboration to Study the Potential of Alpha DaRT to Enhance Immune Stimulation in the Treatment of Breast Cancer
JERUSALEM, Jan. 20, 2022 -- (Healthcare Sales & Marketing Network) -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today that it has signed a sponsored research agree... Devices, Oncology Alpha Tau Medical, Alpha DaRT (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 20, 2022 Category: Pharmaceuticals Source Type: news
